Cel-Sci: Impact on Cancer Immunotherapy? Print E-mail
By Vinny Cassano   
Sunday, 24 October 2010 04:24

CEL-SCI Corporation (AMEX:CVM)  announced last week that seven hospital Institutional Review Boards (“IRB”) in India will begin enrollment for the pending world wide Phase III Multikine trial. 

India looks to be a big player in the trial, with Cel-Sci expecting fifteen clinical centers out of an expected forty-eight clinical centers world-wide to be located in that country.  Slowly, but surely, the Phase III approvals are rolling in, but as I've stated before - it's news of the trial commencement that investors and followers of Multikine's progression are waiting for.  The site approvals are nice, but the slow tease is quickly becoming mundane.  Let us know when the first patient has received the treatment and then we'll pop the Dom Perignon.

In the meantime, CEO Geert Kersten presented at a recent Precision IR virtual conference.  Nothing very noteworthy came from this presentation, but Geert did reiterate quite a few key points regarding Multikine.  He emphasized the fact that Multikine is intended to be a first line standard of care, different from any other cancer immunotherapy in what he called the "first generation" of immunotherapies. 

Of note, Geert lumped Dendreon's Provenge in with that first generation.

The difference between the first generation immunotherapies and Multikine - which he considered to be a "second generation" treatment - is that Multikine is an "off the shelf product."  No samples are needed from the patient, as is the case with Provenge. 

Multikine will also be administered before the patient receives chemotherapy or radiation treatments.  That goes in line with what I consider to be common sense - an immunotherapeutic treatment will work better when the treatment has an immune system that is still in tact to work with.  Chemo and radiation kill the immune system, so I've never quite understood why the new breed of cancer vaccines were only being tested in patients who have already received those treatments.  If successful, Multikine could set the standard.

Mr. Kersten also mentioned the manufacturing facility located near Baltimore, Maryland, which currently has the capicity to produce 20,000 doses in a year.  Within a year and a half, that number could triple.

This is all information that we've all heard before, but I think it's good to be reminded of the true potential of Multikine if this product makes it to market.  Ignore the investing standpoint for a moment and consider the impact that Multikine - like Provenge - could have on the way that the human race treats cancer.  For decades cancer patients have had to fight not only the cancer that succumbs their bodies, but also the very treatments that heal them. 

Treatments such as Provenge and Multikine could be game changers, and could mark a shift in cancer treatment for the ages.

That said, it's yet to be seen if Multikine works as advertised, hence the Phase III trial.

Slowly the site approvals are being announced, and it's only a matter of time before this trial starts.  It should be fun, not just from an investing standpoint, but for the very fact that Multikine could make history.

The risk in a CVM investment is well worth the rewards, in my opinion, although it's worth noting that aside from Provenge, cancer immunotherapies have been highly unsuccessful in coming to market.

 

Disclosure:  Long CVM.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter